Navigation Links
R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
Date:7/21/2009

mit at any of the prescribed time points. In the 5-day repeated-dose study, in the morning and at night 2 ml of RK-023 preparation or 2 ml of placebo was applied to 6 and 2 out of 8 healthy adult males respectively. No serious adverse event was observed during the total 9 times of application up to the morning of day 5. When the drug concentration in the blood was measured, the level was below the quantification limit as in the case of the single-dose study.

As described above, percutaneous absorption of the drug was not high even after continuous application in the morning and at night for 5 days, suggesting hardly any safety problem.

Yukihiko Mashima, Representative Director and President of R-Tech Ueno, commented as follows. "We are pleased to announce the successful completion of a phase 1 clinical study on our self-developed RK-023 that focuses on the dermatology field. We intend to start a phase 2 clinical study in Japan as scheduled and at the same time proceed with full-scale negotiations for partnership at home and abroad."

Having obtained the results of the above-mentioned phase 1 clinical study, we plan to promptly conduct a phase 2 clinical study and accelerate our efforts to develop a drug that will become useful for the patients with androgenetic alopecia as soon as possible.

Note: Androgenetic alopecia:

Due to the influence of male hormones during and after puberty, thick and long hair does not regenerate but is replaced with thin and short soft hair, and consequently the hair follicles become atrophied, reducing the quantity of hair, localized from the parietal to the frontal region.

*About R-Tech Ueno, Ltd.

R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Led by Dr. Yukihiko Mashima, Representative Director and President of R-Tech Ueno, this pharmaceutical venture enterprise has
'/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
3. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
4. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
7. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
8. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
9. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
10. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
(Date:1/22/2015)... Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ... first member of the new Simple Plex platform through ... launch represents the re-branding of the previously acquired CyPlex ... platform is a transformative immunoassay technology which integrates an ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... Technologies Inc., the leading developer of non-invasive electrocardiographic ... $7.5 million Series "C" financing.  The proceeds from ... commercial efforts related to its ECVUE ™ ... (Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO ) CardioInsight recently ...
...  MAKScientific, LLC, a privately held company focused on the ... that it has entered into an exclusive, worldwide option ... BIIB ) to develop and commercialize drug candidates for ... diseases. Under the agreement, Biogen Idec will ...
Cached Medicine Technology:CardioInsight Announces Closing of $7.5 Million Equity Financing 2
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... come out with a novel method of measuring the ... strata of people //and their level of affluence, which ... important causes are most often eliminated while studying the ... risk evaluation based on the inclusion of new parameters, ...
... Pharmaceutical Benefits Scheme (PBS) 'measure and share' proposals, ... groups. // ,AMA President, Dr Mukesh Haikerwal, ... changed prescribing patterns must be re-invested back into ... other education strategies, including details of comparative prescribing ...
... on psychiatric units' activity from the Health Research Board ... Irish psychiatric units and hospitals //continued to fall in ... to 21,253 admissions in 2005, demonstrating a decrease of ... ,Non-voluntary admissions did not show any decline and it ...
... by Irishhealth.com has indicated the meager support for the ... Irish Health Service. //Only one among three individuals thought ... Clinic in Waterford and the 183-bed Beacon Hospital in ... the registered users who were queried, only 34% expressed ...
... fastest growing problem in India with nearly 8 lakh fresh ... //as it has witnessed a sharp rise in the number ... medical camp for breast cancer screening on the National Cancer ... among Indian women followed by cervical cancer. ...
... surgeon Jayant Patel, referred as "Dr Death" by the ... further investigations //on the death of another patient of ... that some of Patel's victims have instructed Nicol Robinson ... unprecedented step of initiating civil action to recover compensation ...
Cached Medicine News:
Iron Total (TIBC) (Iron Buffer + Iron Color=Std.). An Automated analyzer test kits....
Intended for the quantitative determination of iron in serum. Reaction: Endpoint. Wavelength: 595 nm. Linearity: 500 g/dL (89.5 mol/L). Two vials, liquid reagents....
HDL Cholesterol, liquid....
Cholesterol/HDL Standard 50 mg/dl....
Medicine Products: